Tarsus Pharmaceuticals, Inc. TARS Deferred Tax Assets, Valuation Allowance
Deferred Tax Assets, Valuation Allowance at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsValuationAllowance.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-K, filed February 23, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s deferred tax assets, valuation allowance.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s deferred tax assets, valuation allowance?
- Tarsus Pharmaceuticals, Inc. (TARS) reported deferred tax assets, valuation allowance of $107.94M in Q4 2025.
- How has Tarsus Pharmaceuticals, Inc.'s deferred tax assets, valuation allowance changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s deferred tax assets, valuation allowance increased by 22.6% year-over-year, from $88.04M to $107.94M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s deferred tax assets, valuation allowance?
- Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s deferred tax assets, valuation allowance has grown at a 70.6% compound annual growth rate (CAGR), from $7.48M to $107.94M.